Non-Human Primate (NHP) Application in Immunogenicity & Off-Target Safety

Are you currently facing unpredictable immune responses, critical translational safety gaps, and the risk of severe toxicities (CRS, ICANS) in your advanced therapy pipeline? Our specialized NHP services streamline preclinical safety and immunogenicity assessment, helping you de-risk clinical trials through high-fidelity NHP models and cutting-edge translational bioanalysis.

NHP Models Are Vital for Evaluating Safety in Cell and Gene Therapies

NHP models, owing to their close phylogenetic relationship, offer the sole relevant in vivo setting for assessing life-threatening toxicities and unpredictable immune responses of complex cell and gene therapies, forming the foundation of a successful IND submission.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

The development of modern biotherapeutics—including monoclonal antibodies, bispecifics, cell therapies, and gene therapies —is fundamentally reliant on robust preclinical safety data. A key area of failure and risk is immune safety, encompassing two main challenges: immunogenicity and off-target immune-mediated toxicity. Immunogenicity is the propensity of a therapeutic protein or vector to elicit an immune response that compromises efficacy or safety. Off-target safety involves assessing life-threatening, human-specific phenomena such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). A successful preclinical program must accurately anticipate and mitigate these risks before First-in-Human (FIH) trials.

Why Choose Us?

NHPs remain the non-clinical model of choice for advanced therapies because they provide the closest physiological, genetic, and immunological relevance to human biology.

Genetic & Immunological Similarities: NHPs possess T-cell receptor (TCR) and Major Histocompatibility Complex (MHC) profiles that are phylogenetically closest to humans, enabling the modeling of complex, human-specific immune reactions like the systemic inflammatory cascades seen in CRS.
Clinical Translational Relevance: NHPs allow for the investigation of systemic drug and vector fate (PK/PD) integrated with immune safety responses in an intact, functional circulatory and nervous system, which is impossible in in vitro or simpler rodent models.
Vector Biodistribution & Shedding: For Gene Therapies, NHPs are essential for the regulatory-required assessment of AAV vector biodistribution, shedding in body fluids, and vector persistence over time.
Comprehensive Systemic Evaluation: Only NHP models enable the simultaneous assessment of exposure (PK), efficacy markers (PD), and complex safety endpoints (Toxicology, Immunogenicity, Neurotoxicity) within the same experimental cohort.

Key Applications

Creative Biolabs leverages NHP models to provide highly specific data essential for the clinical de-risking of advanced therapies.

CRS and ICANS Modeling: NHPs allow for the administration of CAR-T cells, bispecifics, or other immune cell engagers under conditions that mimic the clinical setting. This enables the measurement of the systemic release of human-relevant cytokines and chemokines to quantify the magnitude of the inflammatory response, which is crucial for determining the Minimal Anticipated Biological Effect Level. Furthermore, NHPs are used to monitor clinical signs of central nervous system involvement associated with ICANS.
Vector Biodistribution and Persistence Studies: For AAV and Lentiviral Gene Therapies, NHPs serve as the definitive model to track vector delivery, tropism, and gene expression across multiple target and non-target tissues. They also provide critical data on vector shedding kinetics in feces, urine, and saliva, directly supporting regulatory safety requirements.
ADA Interference and Risk Assessment: While NHP immunogenicity is not perfectly predictive of human response, it is indispensable for assessing the impact of clearing or neutralizing ADAs on the drug's exposure (PK) and therapeutic effect (PD). NHP studies reveal whether an immune response is sufficient to neutralize the drug, shorten its half-life, and compromise the interpretability of long-term safety data, informing necessary dose adjustments.
On-Target/Off-Tumor Toxicity Profiling: In oncology and autoimmune applications, NHPs allow for the investigation of the therapeutic agent's interaction with the target antigen in normal, non-diseased tissue. This is critical for assessing the potential for non-therapeutic, life-threatening toxicities arising from unintended activity in vital organs.

How Do Creative Biolabs Support Your Projects?

Creative Biolabs offers an integrated suite of services designed to generate the high-quality NHP data required for successful regulatory submissions.

Service Capability	Corresponding Application Area
Cytokine/Chemokine Multiplex Assays	CRS and ICANS Monitoring: Rapid, high-sensitivity profiling of inflammatory biomarkers from NHP plasma/serum during immune-engaging therapy.
Advanced Therapy Safety (Gene/Cell Therapy)	Comprehensive design and execution of NHP toxicology studies focused on novel immune risks and vector integration.
Vector Copy Number (qPCR, ddPCR)	Precise quantitation of vector genomes and transcripts in various NHP matrices (tissue, CSF, body fluids) to meet regulatory biodistribution requirements.
ADA & Neutralizing Antibody (NAb) Assays	Tiered approach (screening, confirmatory, NAb) for detecting and characterizing Anti-Drug Antibodies that may impact drug PK/PD.

Translational Impact

Leveraging Creative Biolabs' NHP immune safety data translates directly into reduced clinical risk and a streamlined path to market.

Early Detection of Immune Responses: Early detection of clearing Anti-Drug Antibodies (ADAs) in NHPs prevents large-scale clinical failures by revealing significant PK/PD interference that would necessitate protocol amendments or termination in human trials.
Regulatory Compliance: NHP biodistribution and shedding data for vector-based therapies are often required for Gene Therapy IND submissions, making these studies non-negotiable regulatory milestones.
Informed Dose Selection: The integration of NHP PK/PD data ensuring that FIH trials begin with a dose that is both safe and pharmacologically relevant, thereby increasing the reliability of early proof-of-concept.

Frequently Asked Questions

Q: What is the sensitivity and specificity of Creative Biolabs' ADA and NAb assays in NHP samples?

A: Our assays are developed and validated using a tiered approach that meets all regulatory expectations, focusing on a high sensitivity screening cutoff and robust specificity via confirmatory assays. We utilize advanced platforms like ELISA, ensuring reliable and reproducible characterization of the anti-drug immune response. Please reach out to review our method validation packages.

Q: How reliable are NHP models for predicting CRS severity in humans, and can you differentiate ICANS?

A: While no animal model perfectly replicates human CRS/ICANS, the NHP's highly similar immune system provides the best in vivo translational context. Our integrated approach measures the relevant human cytokine response and couples this with detailed clinical and neurological observations to differentiate signs of systemic inflammation (CRS) from potential neurotoxic effects (ICANS), providing essential risk signals that guide clinical monitoring plans.

Q: For advanced therapies, which NHP species do you recommend, and what is your sample stability protocol?

A: The choice of NHP species depends heavily on target cross-reactivity and regulatory jurisdiction. We primarily use Cynomolgus and Rhesus macaques, consulting closely with your team to select the optimal model. All biological samples (PBMCs, plasma, tissues) are processed immediately post-collection, aliquoted, and banked under strict cold-chain management, ensuring maximum sample integrity and quality for subsequent bioanalysis.

Q: How do NHP immune safety studies compare to using humanized mouse models for assessing immunogenicity risk?

A: Humanized mouse models are valuable early screening tools, but they lack a fully integrated, functional human-like immune system, circulatory system, and CNS. NHP studies provide a non-surgical, system-wide environment that better reflects human physiology, allowing for the assessment of systemic PK/PD interaction and complex immune toxicity that simple humanized models cannot capture. They are essential for regulatory safety packages.

Contact Us

We are the trusted partner for de-risking advanced therapies, offering unparalleled expertise in NHP immune safety and translational bioanalysis, from ADA assays to complex CRS/ICANS monitoring. To learn more about how our NHP Applications in Immunogenicity & Off-Target Safety services can accelerate your pipeline and ensure regulatory success, please connect with our team today.